Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

  2. Share Prices
  3. Destiny Pharma. Share Price
  4. Destiny Pharma. Share News
  5. IN BRIEF: Destiny Pharma confirms phase 3 development for lead asset

Pin to quick picksDestiny Pharma. Share News (DEST)

Destiny Pharma. Information

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.50
Bid: 17.00
Ask: 18.00
Change: 0.50 (2.94%)
Spread: 1.00 (5.882%)
Open: 17.50
High: 17.50
Low: 17.50
Prev. Close: 17.00
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Destiny Pharma confirms phase 3 development for lead asset

Thu, 06th Jul 2023 12:49

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Confirms proposed phase three development pathway and identifies new life cycle management targets for its XF-73 Nasal programme. Says antimicrobial properties of XF-73 Nasal give greater flexibility in the scheduling of surgeries. Adds there is potential to explore new life management indications, particularly in children.

Interim Chief Executive Officer Debra Barker says: "Destiny Pharma is on the right path and that XF-73 Nasal provides a much-needed addition to the armoury against antimicrobial resistance and surgical site infections."

Current stock price: 27.26 pence, up 4.9% on Thursday

12-month change: down 29%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Nov 2018 13:09

Destiny Pharma Biofilm Project With Southampton Uni Secures Funding

LONDON (Alliance News) - Destiny Pharma PLC said Thursday it had been jointly granted funding with the University of Southampton to examine the use of its technology to eradicate clinical caused a

Read more
25 Oct 2018 11:23

Destiny Pharma Hires Creabilis's Shaun Claydon As New Finance Head

LONDON (Alliance News) - Destiny Pharma PLC said on Thursday it has appointed Shaun Claydon as its new finance chief after the departure of Chief Financial Officer Simon Sacerdoti.Claydon,

Read more
19 Oct 2018 14:54

Destiny Pharma helps with new bioindustry association videos

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma noted the launch of a series of videos and explainer documents from the UK BioIndustry Association (BIA) celebrating UK bioscience and revealing the research and development taking place in biotech companies around the UK on Friday.

Read more
26 Sep 2018 12:39

Destiny Pharma Loss More Than Doubles On Administrative Expenses

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday reported a substantial widening of its loss in the first half of the year due to administrative expenses.The clinical stage company

Read more
6 Sep 2018 13:24

Destiny Pharma Chairman Nigel Rudd To Step Down In December

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that Chairman Nigel Rudd stepped down from the company in December after eight years.Non-Executive Director Nick Rodgers will Rudd

Read more
6 Sep 2018 10:32

Chairman of Destiny calling time after 15 years with pharma firm

(Sharecast News) - Clinical stage biotechnology firm Destiny Pharma revealed on Thursday that long-time chairman Nigel Rudd was stepping down from the board on 31 December after eight years.

Read more
26 Jul 2018 13:49

Destiny Pharma Receives Positive Results From Skin Irritation Study

LONDON (Alliance News) - Destiny Pharma PLC said Thursday that it received positive data from the Phase I of its XF-73 skin irritation study.The clinical stage biotechnology company said is

Read more
21 Jun 2018 10:25

Destiny Pharma Appoints SEHTA Chairman Nick Rodgers As Non-Executive

LONDON (Alliance News) - Anti-microbial resistance-focused biotechnology developer Destiny Pharma PLC said Thursday it has appointed Nick Rodgers as an independent non-executive director with is a

Read more
30 May 2018 13:00

Destiny Pharma Creates Independent Scientific Advisory Board

LONDON (Alliance News) - Destiny Pharma PLC said Wednesday it has formed a scientific advisory board to provide "expert, independent analysis" of the company's research and clinical

Read more
123456789

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.